This study is a single-center, prospective, single-arm study of the efficacy of double-dose Furmonertinib in the treatment of patients with slow Osimertinib-resistant non-small cell lung cancer, mainly in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations in stage IIIB or IV, slow drug resistance after treatment with Osimertinib, and no therapeutic target was found by secondary biopsy after drug resistance.
Age ≥ 18 years old;
EGFRm NSCLC of local progression (IIIB stage) or metastasis (IV stage);
previously confirmed to have EGFR (Ex19del or L858R) mutation, or T790M, received Osimertinib treatment. According to Recist 1.1 imaging findings, the focus progressed slowly and there was no systemic explosive progress (definition of slow progress: disease control > 6 months, slightly increased tumor load and symptom score ≤ 1);
patients who intend to use Furmonertinib (double dose, 160mg) anticancer therapy;
Patients who have been treated with Furmonertinib;
Patients who intend to use anticancer therapy other than Furmonertinib recently;
Contraindications for the use of Furmonertinib;